|  |  |
| --- | --- |
| **Consultation Response Form** | Your name:  Organisation (if applicable):  email / telephone number:  Your address: |

**Consultation questions**

|  |  |
| --- | --- |
| **Q1.** | **Do you consider that the temporary approval has had a positive impact on the provision of abortion services for women accessing these services with particular regard to safety, accessibility and convenience of services? Please provide your reasons.** |

|  |  |
| --- | --- |
| **Q2.** | **Do you consider that the temporary measure has had a positive impact on the provision of abortion services for those involved with service delivery? This might include greater workforce flexibility, efficiency of service delivery, value for money etc. Please provide your reasons.** |

|  |  |
| --- | --- |
| **Q3.** | **What risks do you consider are associated with the temporary measure? If you consider that there are risks, can these risks be mitigated?** |

|  |  |
| --- | --- |
| **Q4.** | **In your experience, have other NHS Wales services been affected by the temporary approval? If so, which?** |

|  |  |
| --- | --- |
| **Q5.** | **Outside of the Covid-19 pandemic, do you consider there are benefits in relation to safeguarding and women's safety in requiring them to make at least one visit to a service to be assessed by a clinician? Please outline those benefits.** |

|  |  |
| --- | --- |
| **Q6.** | **To what extent do you consider making permanent home use of both pills could have a differential impact on groups of people or communities? For example, what is the impact on people with a disability or on people from different ethnic or religious backgrounds?** |

|  |  |
| --- | --- |
| **Q7.** | **To what extent do you consider that making permanent home use of both pills for EMA would increase or reduce the difference in access to abortion for people from more economically disadvantaged areas or between geographical areas with different levels of disadvantage?** |

|  |  |
| --- | --- |
| **Q8.** | **Should the temporary measure enabling home use of both pills for EMA:**   1. **Become a permanent measure?** 2. **Remain unaffected (i.e. be time limited for two years and end two years after the Coronavirus Act came into force (25 March 2022), or end on the day on which the temporary provision of the Coronavirus Act 2020 expire, whichever is earlier).** 3. **Other [please provide details]?** |

|  |
| --- |
| Responses to consultations are likely to be made public, on the internet or in a report.  If you would prefer your response to remain anonymous, please tick here: |